Egetis Therapeutics: Short Comment on Capital Markets Day - Redeye

Redeye is encouraged by yesterday’s capital market day, which further emphasized that Egetis has a clear and derisked way to the market with lead project Emcitate. We give a short comment and will return with an updated view of the company within a month.

Länk till analysen i sin helhet: https://www.redeye.se/research/858077/short-comment-on-capital-markets-day?utm_source=finwire&utm_medium=RSS